TERN - CIK 0001831363
Terns Pharmaceuticals, Inc. (TERN) reported net income of -$96.21M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$96.21M | -8.3% |
| FY 2024 | -$88.85M | +1.5% |
| FY 2023 | -$90.21M | -49.5% |
| FY 2022 | -$60.34M | -20.3% |
| FY 2021 | -$50.16M | -25.2% |
| FY 2020 | -$40.05M | - |
Terns Pharmaceuticals, Inc. (TERN) reported net income of -$96.21M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2020 and fiscal 2025, Terns Pharmaceuticals, Inc.'s net income declined from -$40.05M to -$96.21M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.